<!DOCTYPE html>
<html>
<head>
<title>HCV Decision Support</title>
<link rel="stylesheet" href="https://ajax.googleapis.com/ajax/libs/jqueryui/1.11.4/themes/smoothness/jquery-ui.css">
<script src="https://ajax.googleapis.com/ajax/libs/jquery/2.1.3/jquery.min.js"></script>
<script src="https://ajax.googleapis.com/ajax/libs/jqueryui/1.11.4/jquery-ui.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.blockUI/2.66.0-2013.10.09/jquery.blockUI.js"></script>
 
<style>

p,td,input,div,select { font-family: sans-serif; font-size:1em;}
td { padding: 2px 0;}
label { float:right; padding-right:3px;}
button:focus {outline:0;}

.narrow { width:40px; font-size:0.8em;}
.notes { font-size:0.9em;}
.red { color:red;}
.green { color:green;}
.title { font-weight: 700; padding-top:0.5em;}
.grading { font-size:0.9em;}
.nowrap { white-space: nowrap;}

@media print {
    #print { display:none;}
    #dataInput { display:none;}
}

</style>
</head>

<body>

<script>
var version = '1.3';

var ratings = {
    classILevelA   : 'Class I, Level A',
    classILevelB   : 'Class I, Level B',
    classIILevelA  : 'Class II, Level A',
    classIILevelB  : 'Class II, Level B',
    classIIaLevelA : 'Class IIa, Level A',
    classIIaLevelB : 'Class IIa, Level B',
    classIIbLevelA : 'Class IIb, Level A',
    classIIbLevelB : 'Class IIb, Level B',
    A1: 'A1 - High Quality Evidence, Strong Recommendation',
    A2: 'A2 - High Quality Evidence, Weak Recommendation',
    B1: 'B1 - Moderate Quality Evidence, Strong Recommendation',
    B2: 'B2 - Moderate Quality Evidence, Weak Recommendation',
    C1: 'C1 - Low Quality Evidence, Strong Recommendation',
    C2: 'C2 - Low Quality Evidence, Weak Recommendation'
}

var drugs = {
    sof: {
        generic: 'Sofosbuvir',
        dose: ['400mg'],
        brand: [
        'Solvadi',
        'Hopetavir (Incepta)',
        'Sofovir (Hetero)',
        'Hepcinat (Natco)',
        'Soforal (Beacon)',
        'Hepcvir (Cipla)',
        'Sofovir-C (Beximco)',
        'Hepcee (Julphar)',
        'MyHep (Mylan)'
        ],
        route: 'PO',
        freq: 'daily',
        notes: []
   },
    sof_led: {
        generic: 'Sofosbuvir/Ledipasvir',
        dose: ['400mg/90mg'],
        brand: [
        'Harvoni',
        'Twinvir (Incepta)',
        'Hepcvir-L (Cipla)',
        'Ledifos (Hetero)',
        'Hepcinat LP (Natco)',
        'Lesovir-C (Beximco)',
        'Combicee (Julphar)',
        'MyHep LVIR (Mylan)'
        ],
        route: 'PO',
        freq: 'daily',
        notes: ['In the ION-3 trial, patients without cirrhosis and a baseline HCV RNA levels less than 6 million IU/mL had similar relapse rates when treated with 8 weeks versus 12 weeks. Decreasing the length of the regimen to 8 weeks should be done with caution.'
        ]
    },
    dac: {
        generic: 'Daclatasvir',
        dose: ['60mg','30mg'],
        brand: [
        'Daklinza',
        'Virodacla (Incepta)',
        'Daclahep (Hetero)',
        'Daclavir (Beacon)',
        'Daclacee (Julphar)'
        ],
        route: 'PO',
        freq: 'daily',
        notes: ['The dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively.'
        ]
    },
    riba: {
        generic: 'Ribavirin',
        dose: ['200mg','400mg','600mg'],
        brand: [
        'Ibavyr',
        'Celbarin (Incepta)',
        'Ribacee (Julphar)'
        ],
        route: 'PO',
        freq: 'daily divided into 2 doses',
        notes: []
    },
    viek: {
        generic: 'Paritaprevir/Ritonavir/Ombitasvir',
        dose: [ '75mg/50mg/12.5mg' ],
        brand: [ 'Viekira Pak' ],
        route: 'PO',
        freq: 'two tablets once daily',
        notes: ['Contraindicated in patients with Child-Turcotte-Pugh class B or C hepatic impairment.']
    },
    viekx: {
        generic: 'Dasabuvir',
        dose: [ '250mg' ],
        brand: [ 'Viekira Pak' ],
        route: 'PO',
        freq: 'twice daily',
        notes: []
    },
    peg: {
        generic: 'PegInterferon-&alpha;2a',
        dose: [ '180&mu;g'],
        brand: [ 'Pegasys' ],
        route: 'SC',
        freq: 'weekly',
        notes: [
            'Treatment of chronic hepatitis C with PegIFN-a and ribavirin containing regimens is absolutely contra-indicated in the following patient groups: uncontrolled depression, psychosis or epilepsy; pregnant women or couples unwilling to comply with adequate contraception; severe concurrent medical diseases and comorbidities including retinal disease, autoimmune thyroid disease; decompensated liver disease.',
            'The use of PegIFN-a is not recommended in patients with absolute neutrophil counts &lt;1500/mm3 and/or platelet counts &lt;90,000/mm3.'
        ]
    },
    peg2b: {
        generic: 'PegInterferon-&alpha;2b',
        dose: [ '1.5&mu;g/kg'],
        brand: [ 'PegIntron' ],
        route: 'SC',
        freq: 'weekly',
        note: []
    },
    sim: {
        generic: 'Simeprevir',
        dose: [ '150mg' ],
        brand: [ 'Olysio' ],
        route: 'PO',
        freq: 'daily',
        notes: ['Not recommended in patients who have a detectable Q80K substitution in the NS3 protease sequence at baseline, as assessed by population sequencing (direct sequence analysis)']
    }
};

var svrx = {
    gt1: {
        sof_led: {
            default: 97,
            rating: {
                aasld: ratings.classILevelA,
                easl: ratings.A1
            },
            gt1a: {
                default: 97, // ION-1 98% (142/145) ION-3 96% 96% (165/172) Aggregate 96.8% (307/317)
                rating: {
                    aasld: ratings.classILevelA,
                    easl: ratings.A1                                   
                }
            },
            gt1b: {
                default: 99, // ION-1 100% (67/67) ION-3 98% (43/44) Aggregate 99.1% (110/111)
                rating: {
                    aasld: ratings.classILevelA,
                    easl: ratings.A1                                  
                }
            },
            f4: { 
                default: 97,
                rating: {
                    aasld: ratings.classILevelB,
                    easl: ratings.B1                                   
                },
                w12: 97,      // ION-1 97% (32/33)
                w12riba: 100, // ION-1 100% (33/33)
                w24: 97,      // ION-1 97% (31/32)
                w24riba: 100  // ION-1 100% (36/36)
            },
            fail: {
                default: 94,
                rating: {
                    aasld: ratings.classILevelB,
                    easl: ratings.B2
                },
                w12: 94,     // ION-3 94% (102/109) 
                w12riba: 96, // ION-3 96% (107/111) 
                w24: 99,     // ION-3 99% (108/109) 
                w24riba: 99  // ION-3 99% (110/111)
            }

        },
        sof_dac: {
            default: 98,  // ALLY-2  naive (80/83) experienced (43/44) NB HIV Coinfected AI444040 (24wk) 100% (44/44) Aggregate 97.6% (167/171)
            rating: {
                aasld: ratings.classILevelB,
                easl: ratings.A1
            },
            gt1a: {
                default: 96, // ALLY-2 naive 96% (68/71) experienced 97% (32/33) Aggregate 96.2% (100/104)
                rating: {
                    aasld: ratings.classILevelB,
                    easl: undefined
                }
            },
            gt1b: {
                default: 100, // ALLY-2 naive 100% (12/12) experienced 100% (11/11)
                rating: {
                    aasld: ratings.classILevelB,
                    easl: undefined
                }
            },
            f4: {
                default: 91, // ALLY2 naive 89% (8/9) experienced 92% (12/13) Aggregate 90.9 (20/22)
                rating: {
                    aasld: undefined,
                    easl: ratings.B1
                },
            },
            fail: {
                default: 91
            }
        },
        sof_sim: {
            default: 89, // TARGET 2.0 89% (269/303) TRIO 90% (263/292) Aggregate 89.4% (532/595)
            rating: {
                aasld: ratings.classILevelA,
                easl: ratings.A1
            },
            gt1a: {
                default: 91, // TARGET 2.0 89% (47/53) TRIO 92% (79/86) Aggregate 90.6% (126/139)
                rating: {
                    aasld: ratings.classILevelA,
                    easl: ratings.A1
                }
            },
            gt1b: {
                default: 96, // TARGET 2.0 95% (88/93) TRIO 98% (39/40) Aggregate 95.5% (127/133)
                rating: {
                    aasld: ratings.classILevelA,
                    easl: ratings.A1
                }
            },
            f4: {
                rating: {
                    aasld: undefined,
                    easl: ratings.B1
                },
                w12: 84,     // COSMOS 93% (13/14) TRIO 83% (110/133) Aggregate 83.7% (123/147)
                w12riba: 93, // COSMOS 96% (25/27)
                w24: 93,    // COSMOS 100% (16/16) Downgraded from 100% due to sample size/outlier
                w24riba:93   // COSMOS 79% (28/30)                
            },
            fail: {
                w12: 88,     // COSMOS 93% (13/14) TRIO 87% (137/157) Aggregate 87.7% (150/171)
                w12riba: 96, // COSMOS 96% (26/27)
                w24: 93,     // COSMOS 93% (14/15)
                w24riba:79   // COSMOS 79% (19/24)
            }
        },
        viek: {
            default: 90,
            rating: {
                aasld: ratings.classILevelA,
                easl: ratings.A1
            },
            gt1a: {
                default: 90, // PEARL-IV 90% (185/205)
                rating: {
                    aasld: ratings.classILevelA,
                    easl: ratings.A1
                }
            },
            gt1b: {
                default: 99, // PEARL-III 99% (207/209)
                rating: {
                    aasld: ratings.classILevelA,
                    easl: ratings.A1
                }
            },
            f4: {},
            fail: {
                gt1b: 100 // PEARL-II 100% (91/91)
            }
        },
        viek_riba: {
            default: 97,
            rating: {
                aasld: ratings.classILevelA,
                easl: ratings.A1
            },
            gt1a: {
                default: 96, // SAPHIRE-I 95% (307/322)// PEARL-IV 97% (97/100) Aggregate 95.7% (404/422)
                rating: {
                    aasld: ratings.classILevelA,
                    easl: ratings.A1
                }
            },
            gt1b: {
                default: 99, // SAPHIRE-I 98% (148/151) PEARL-III 99% (209/210) Aggregate 98.9% (357/361)
                rating: {
                    aasld: ratings.classILevelA,
                    easl: ratings.A1
                }
            },
            f4: {
                w12: 92,  // TURQUOISE-II 92% (191/208)
                w24: 96,  // TURQUOISE-II 96% (165/172)
                gt1a: 92, // TURQUOISE-II 92% (239/261)
                gt1b: 99  // TURQUOISE-II 99% (118/119)
            },
            fail: {
                default: 96,
                gt1a: 96, // SAPHIRE-II 96% (166/173)
                gt1b: 97  // SAPHIRE-II 97% (119/123) PEARL-II 97% (85/88)
            }
        },
        sof_peg_riba: {
            default: 87, // NEUTRINO 89% (259/291) TARGET2.0 90% (114/127) TRIO 81% (112/138) Aggregate  87.2% (485/556)
            rating: {
                aasld: undefined,
                easl: ratings.A1
            },
            gt1a: {
                default: 92, // NEUTRINO 92% (206/225)
                rating: {
                    aasld: undefined,
                    easl: ratings.A1
                }
            },
            gt1b: {
                default: 82, // NEUTRINO 82% (54/66)
                rating: {
                    aasld: undefined,
                    easl: ratings.A1
                }
            },
            f4: {
                default: 77, // NEUTRINO 80% (43/54) TARGET2.0 70% (26/37) TRIO 81% (25/31) Aggregate 77.0% (94/122)
            },
            fail: {
                default: 77, // TRIO 77% (30/39) 
                f4: 62       // TRIO 62% (53/85)
            }
        },
        sim_peg_riba: {
            default: 80, // QUEST-1 80% (210/264) QUEST-2 81 (209/257) Aggregate  80.4% (419/521)
            rating: {
                aasld: undefined,
                easl: ratings.A1
            },
            gt1a: {
                default: 84, // QUEST-1 and QUEST-2 84% (138/165)
                rating: {
                    aasld: undefined,
                    easl: ratings.A1
                }
            },
            gt1b: {
                default: 85, // QUEST-1 and QUEST-2 85% (228/267)
                rating: {
                    aasld: undefined,
                    easl: ratings.A1
                }
            },
            f4: {
                default: 60, // QUEST-1 and QUEST-2 (29/48)
            },
            fail: {
                default: 79, // Aggregate 79.2% (206/260)
                f4: 60,      // QUEST (as above)
                gt1a: 70,    // QUEST 70% (78/111)
                gt1b: 86     // QUEST 86% (128/149)
            }
        }
    },
    gt2: {
        sof_riba: {
            default: 95, // FISSION 97% (58/59) FUSION (12wk) 96% (25/26) POSITRON 92% (85/92) VALENCE 97% (29/30) Aggregate 95.1% (197/207)
            w16: 100,    // FUSION (16wk) 100% (23/23)
            rating: {
                aasld: undefined,
                easl: ratings.A1
            },
            f4: {
                default: 83, // FISSION 91% (10/11) FUSION (12wk) 60% (6/10) POSITRON 94% (16/17) VALENCE 100% (2/2) Aggregate 82.9% (34/41)
                w16: 78,     // FUSION (16wk) 78% (7/9)
                rating: {
                    easl: ratings.B1,
                    duration16: 16,
                    duration20: 20
                }
            },
            fail: {
                default: 92, // FUSION 92% (24/26) VALENCE 91% (30/33) Aggregate 91.5% (54/59)
                w16: 96,     // FUSION 96% (23/24)
                f4: 88       // VALENCE (7/8)
            }
        },
        sof_peg_riba: {
            default: 96, // LONESTAR 96% (22/23)
            rating: {
                aasld: undefined,
                easl: ratings.B1
            },
        },
        sof_dac: {
            default: 92, // UN-NAMED http://www.ncbi.nlm.nih.gov/pubmed/24428467 92% (24/26) AI444040 (24wk) 96% (25/26)
            rating: {
                aasld: undefined,
                easl: ratings.B1
            }
        }
    },
    gt3: {
        sof_peg_riba: {
            default: 90,  // UN-NAMED 90% (9/10) UN-NAMED 91% (20/22) BOSON 95% (117/123) Aggregate 94.1% (146/155)
            rating: {
                aasld: undefined,
                easl: ratings.B1
            },
            f4: {
                default: 88 // BOSON 88% (51/58)
            },
            fail: {
                default: 91 // BOSON 91% (79/87)
            }
        },
        sof_riba: {
            default: 88, // BOSON 24 weeks 88% (83/94) VALENCE 95% (87/92)
            w16: 71, // BOSON 71% (128/181)
            w24: 84, // BOSON 84% (153/182) 
            rating: {
                aasld: undefined,
                easl: ratings.A1
            },
            f4: {
                default: 81  // BOSON 79% (44/56) VALENCE 92% (12/13) Aggregate 81.1% (56/69)
            },
            fail: {
                default: 83, // BOSON 80% (70/88) VALENCE 87% (85/98) Aggregate 83.3% (155/186)
                f4: 62       // VALENCE 62% (29/47)
            }
        },
        sof_dac: {
            // AASLD-2015 http://www.clinicaloptions.com/Hepatitis/Conference%20Coverage/AASLD%202015/Highlights/Capsules/206.aspx
            // Presented at AASLD Nov 2015
            default: 89,    // UN-NAMED IIb (24wk) 89% (16/18) ALLY-3 97% (73/75) AASLD-2015 96% (24/45)
            w24: 100,       // AASLD-2015 100% (29/29)
            rating: {
                aasld: undefined,
                easl: ratings.B1
            },
            f4: {
                default: 65, // ALLY-3 58% (11/19) AASLD-2015 70% (23/33) Aggregate 65.4% (34/52)
                w24: 90,     // AASLD-2015 86% (116/135) overall but Child-Pugh A 90% (90/100)
                riba24: 81   // AASL-2015 81% (39/48)
            },
            fail: {
                default: 86,  // ALLY-3 94% (32/34) AASLD-2015 86% (89/103) (bias by F3/F4)
                f4: 64,       // ALLY-3 69% (9/13) 
                w24: 86,      // AASLD-2015 86% (89/103)
                riba24: 80,   // AASLD-2015 80% (28/35)
            }
        }        

    },
    gt4: {

    },
    gt5: {

    },
    gt6: {

    }
}

function supportDecision () {

    $("#demographics").html('');
    $("#rx").html('');
    var h = {};
    h.genotype  = $("#genotype option:selected").text();
    h.fibrosis  = $("#fibrosis option:selected").text();
    h.harvoniCI = $("input[name=harvoniCI]:checked").val();
    h.guidelines= $("input[name=guidelines]:checked").val();
    h.past      = $("#past option:selected").val();
    h.pastTxt    = $("#past option:selected").text();
    h.riba      = $("#riba:checked").length == 1 ? true : false;
    h.platelets = parseInt($("#platelets").val());
    h.weight    = $("input[name=weight]:checked").val();
    h.eGFR      = $("#eGFR").val();
    h.eGFR      = h.eGFR.replace('>','');
    h.eGFR      = parseInt(h.eGFR);
    h.locale    = h.guidelines == 'AASLD' ? 'en-US' : h.guidelines == 'EASL' ? 'en-GB' : 'en-AU';

    var error = '';
    var errorFocus = ''
    if (h.genotype  == '' ) { 
        error += 'Please select Genotype<br>'; 
        if (errorFocus == '') errorFocus = '#genotype' 
    }
    if (h.fibrosis  == '' ) { 
        error += 'Please select Fibrosis<br>'; 
        if (errorFocus == '') errorFocus = '#fibrosis' 
    }
    if (h.pastTxt   == '' ) { 
        error += 'Please select Past Treament<br>'; 
        if (errorFocus == '') errorFocus = '#past' 
    }
    if (h.harvoniCI === undefined && ! ( h.genotype.match(/2/) || h.genotype.match(/3/) ) ) { 
        error += 'Please select Harvoni CI<br>'; 
        if (errorFocus == '') errorFocus = '#harvoniCI' 
    }
    if (h.riba) {
        if (isNaN(h.platelets)) { 
            error += 'Please input Platelets<br>'; 
            if (errorFocus == '') errorFocus = '#platelets' 
        }
        if (typeof h.weight === "undefined") { 
            error += 'Please select Weight<br>'; 
            if (errorFocus == '') errorFocus = '#weight' 
        }
        if (isNaN(h.eGFR)) { 
            error += 'Please input eGFR<br>'; 
            if (errorFocus == '') errorFocus = '#eGFR' 
        }
    }
    if (error != '') {
        errorDialog(error,errorFocus)
        setTimeout(function(){$("#demographics").html(redText(error))},1000);      
        return;
    }

    h.f4        = h.fibrosis.match(/F4/);
    h.fail      = (h.past == 'naive' || h.past == 'PEG' ) ? false : true;
    h.harvoniCI = (h.harvoniCI == 'yes') ? true : false;

    // visual feedback to user
    blockMessage('Calculating...',500);
    $("#calculate").val('Recalculate');
    setTimeout(function(){doCalculation(h)},450);
}

function doCalculation (h) {

    renderDemographics(h);
    renderRx(h);
}

function renderDemographics(h) {

    var demographics = 'Guidelines:     ' + h.guidelines + '\n' +
                       'Genotype:       ' + h.genotype   + '\n' +
                       'Fibrosis:       ' + h.fibrosis   + '\n' + 
                       'Past Treatment: ' + h.pastTxt    + '\n' +
                       'Past Failure:   ' + h.fail       + '\n' +
                       'Harvoni CI:     ' + h.harvoniCI  + '\n' +
                       'Ribavirin:      ' + h.riba       + '\n';
    if ( h.riba ) {
        demographics += 
                       'Platelets:      ' + h.platelets      + '\n' +
                       'Weight:         ' + h.weight + ' kg' + '\n' +
                       'eGFR:           ' + $("#eGFR").val() + '\n';
    }
    var d = new Date();
    demographics = '<p><b>HCV Decision Support v' + version + ' ' + d.toLocaleString(h.locale) + '</b></p><pre>' + demographics + '</pre>';
    $("#demographics").html(demographics);
} 

function renderRx(h) {

    h.rx = [];
    getRxOptions(h); //alert(JSON.stringify(h));
    var html = '';
    // display by descending SVR
    h.rx.sort(function(a, b){return b.svr-a.svr});

    for ( var m in h.rx ) {
        var svrOdds = Math.round(100/(100-h.rx[m].svr)) - 1;
        var days = h.rx[m].duration == 24 ? '84 days + 1 repeat' : '84 days + no repeats';
        var medication = '';
        for ( var d in h.rx[m].medication ) {
            var drug = h.rx[m].medication[d];
            if ( parseInt(d) > 0 ) medication += drug.optional ? ' &plusmn; ' : ' + ';
            //alert(JSON.stringify(drug));
            medication += drug.generic + ' (' + drug.brand[0] + ') ' + drug.dose[0] + ' ' + drug.route +', ' + drug.freq;
            var drugSort = drug.brand.slice();
            drugSort.sort();
            h.rx[m].notes.push( '<b>' + drug.generic + ' brand names: </b>' + drugSort.join(', '));
        }
        html += '<hr>' +
                '<b>Medications:</b> '   + medication + '<br>' +
                '<b>Duration:</b> '     + h.rx[m].duration + ' weeks (' + days + ')<br>' +
                '<b>Expected SVR:</b> ' + h.rx[m].svr + '% (Odds of SVR are '  + svrOdds + ':1)<br>';

        if (typeof h.rx[m].rating !== 'undefined') html += '<b>Rating:</b> <a href="javascript:evidence()">' + h.rx[m].rating + '</a><br>';

        h.rx[m].notes.unshift('Check for interactions using <a href="http://www.hep-druginteractions.org/Interactions.aspx" target="_new">http://www.hep-druginteractions.org/Interactions.aspx</a>');
        html += '<br><div class="notes"><b>Notes:</b><ol>';
        for (var i in h.rx[m].notes) {
            html += '<li>' + h.rx[m].notes[i] + '</li>';
        }
        html += '</ol></div>';
    }
    html += '<div id="print"><hr><input type="button" value="Print" onclick="window.print()"></div>'
    $("#rx").html(html);
}



function getRxOptions(h) {

    if (h.guidelines == 'AUS') {
        if ( h.genotype.match(/1/) ) rxGT1AUS(h);
        if ( h.genotype.match(/2/) ) rxGT2AUS(h);   
        if ( h.genotype.match(/3/) ) rxGT3AUS(h);
        if ( h.genotype.match(/4/) ) rxGT4AUS(h);
        if ( h.genotype.match(/5/) ) rxGT5AUS(h);
        if ( h.genotype.match(/6/) ) rxGT6AUS(h);       
    }
    else if (h.guidelines == 'EASL') {
        if ( h.genotype.match(/1/) ) rxGT1EASL(h);
        if ( h.genotype.match(/2/) ) rxGT2EASL(h);   
        if ( h.genotype.match(/3/) ) rxGT3EASL(h);
        if ( h.genotype.match(/4/) ) rxGT4EASL(h);
        if ( h.genotype.match(/5/) ) rxGT5EASL(h);
        if ( h.genotype.match(/6/) ) rxGT6EASL(h); 
    }
    else if (h.guidelines == 'AASLD') {
        if ( h.genotype.match(/1/) ) rxGT1AASLD(h);
        if ( h.genotype.match(/2/) ) rxGT2AASLD(h);   
        if ( h.genotype.match(/3/) ) rxGT3AASLD(h);
        if ( h.genotype.match(/4/) ) rxGT4AASLD(h);
        if ( h.genotype.match(/5/) ) rxGT5AASLD(h);
        if ( h.genotype.match(/6/) ) rxGT6AASLD(h); 
    }
    else if (h.guidelines == 'FIXHEPC') {
        if ( h.genotype.match(/1/) ) rxGT1(h);
        if ( h.genotype.match(/2/) ) rxGT2(h);   
        if ( h.genotype.match(/3/) ) rxGT3(h);
        if ( h.genotype.match(/4/) ) rxGT4(h);
        if ( h.genotype.match(/5/) ) rxGT5(h);
        if ( h.genotype.match(/6/) ) rxGT6(h);       
    }
    else {
        alert('OMG, the flux capacitor has imploded!');
    }

}


/*
*
*
*
* AUS Treatment Protocols
*
*
*
*/

function rxGT1AUS (h) {

    // sof dac
    h.rx.unshift({ 
        medication:[ drugs.sof, drugs.dac ], 
        duration: 12,
        svr: svrx.gt1.sof_dac.default, 
        notes: []
    });
    pushNotes(h.rx[0]);
    if ( h.past == 'PROTEASE' ) {
        h.rx[0].duration = 24;
        h.rx[0].svr = svrx.gt1.sof_dac.fail.default;
        h.rx[0].notes.push('24 weeks recommended for patients who have failed a protease inhibitor');
    }
    if ( h.f4 ) {
        h.rx[0].svr = svrx.gt1.sof_dac.f4.default;
        if ( h.past != 'PROTEASE' ) {
            h.rx[0].notes.push(redText('Consider adding Ribavirin or extending treatment to 24 weeks'));
        }
    }
    // viekira pak
    h.rx.unshift({
        medication: [ drugs.viek, drugs.viekx ],
        duration: 12,
        svr: svrx.gt1.viek.gt1b.default,
        notes: []
    });
    pushNotes(h.rx[0]);
    if ( ! h.genotype.match(/1b/)) {
        addRiba(h,false);
        h.rx[0].svr = svrx.gt1.viek_riba.gt1a.default;

    }
    // harvoni
    if (hasHarvoniCI(h)) return;
    h.rx.unshift({
        medication: [ drugs.sof_led ],
        duration: 12,
        svr: svrx.gt1.sof_led.default,
        notes: []
    });
    pushNotes(h.rx[0]);
    if ( h.genotype.match(/1b/)) h.rx[0].svr = svrx.gt1.sof_led.gt1b.default;
    if ( h.f4 && h.fail ) {
        h.rx[0].duration = 24;
        h.rx[0].svr      = svrx.gt1.sof_led.fail.w24;
        h.rx[0].notes.push('12 weeks + Ribavirin may be considered');
    }
    if ( ! h.fail && ! h.f4 ) {
        h.rx[0].notes.push('8 weeks may be considered if HCV RNA < 6 x 10^6 IU/ml');
    }
}

function rxGT2AUS (h) {

    // sof riba
    h.rx.unshift({
        medication: [ drugs.sof ],
        duration: 12,
        svr: svrx.gt2.sof_riba.default,
        notes: []
    });
    pushNotes(h.rx[0]);
    addRiba(h);
    if ( h.f4  || h.fail ) {
        h.rx[0].svr =  h.f4 ? svrx.gt2.sof_riba.f4.default : svrx.gt2.sof_riba.fail.default;
        h.rx[0].notes.push(redText('SVR rates may be increased by extending duration to 16-24 weeks'));
    }
}

function rxGT3AUS (h) {

    // sof dac
    h.rx.unshift({ 
        medication:[ drugs.sof, drugs.dac ], 
        duration: 12,
        svr: 96, 
        notes: [] 
    });
    pushNotes(h.rx[0]);
    if ( h.f4 ) {
        h.rx[0].duration = 24;
        h.rx[0].svr      = 94;
        h.rx.unshift({ 
            medication:[ drugs.sof, drugs.dac ], 
            duration: 16,
            svr: 94, 
            notes: [] 
        });
        addRiba(h);
    }
    // sof riba
    h.rx.unshift({
        medication: [ drugs.sof ],
        duration: 24,
        svr: 93,
        notes: []
    });
    addRiba(h);
    if ( h.f4 ) {
        h.rx[0].svr      = 67;
    }
    // sof peg riba
    h.rx.unshift({
        medication: [ drugs.sof, drugs.peg ],
        duration: 12,
        svr: 85,
        notes: []
    });
    addRiba(h);    
}

function rxGT4AUS (h) {

    // sof peg riba
    h.rx.unshift({
        medication: [ drugs.sof, drugs.peg ],
        duration: 12,
        svr: 90,
        notes: []
    });
    addRiba(h); 
    // sim peg riba
    h.rx.unshift({
        medication: [ drugs.sim, drugs.peg ],
        duration: 48,
        svr: 85,
        notes: [ 'Duration 24-48 weeks']
    });
    addRiba(h);
}

function rxGT5AUS (h) {

    // sof peg riba
    h.rx.unshift({
        medication: [ drugs.sof, drugs.peg ],
        duration: 12,
        svr: 90,
        notes: []
    });
    addRiba(h); 
}

function rxGT6AUS (h) {

    // sof peg riba
    h.rx.unshift({
        medication: [ drugs.sof, drugs.peg ],
        duration: 12,
        svr: 90,
        notes: []
    });
    addRiba(h);    
}

/*
*
*
*
* EASL 2015
*
*
*
*/


function rxGT1EASL (h) {

    // sof peg riba
    h.rx.unshift({
        medication: [ drugs.sof, drugs.peg ],
        duration: 12,
        svr: svrx.gt1.sof_peg_riba.default,
        rating: svrx.gt1.sof_peg_riba.rating.easl,
        notes: []
    });
    pushNotes(h.rx[0]);
    addRiba(h);
    if ( h.genotype.match(/1a/) ) {
        h.rx[0].svr = svrx.gt1.sof_peg_riba.gt1a.default;
    }
    if ( h.genotype.match(/1b/) ) {
        h.rx[0].svr = svrx.gt1.sof_peg_riba.gt1b.default;
    }
    if ( h.f4 ) {
        h.rx[0].svr = svrx.gt1.sof_peg_riba.f4.default;
    }
    if ( h.fail ) {
        h.rx[0].svr = h.f4 ? svrx.gt1.sof_peg_riba.fail.f4 : svrx.gt1.sof_peg_riba.fail.default;
    }

    // sim peg riba
    h.rx.unshift({
        medication: [ drugs.sim, drugs.peg ],
        duration: 12,
        svr: svrx.gt1.sim_peg_riba.default,
        rating: svrx.gt1.sim_peg_riba.rating.easl,
        notes: [ 'HCV RNA levels should be monitored on treatment. Treatment should be stopped if HCV RNA level is ≥25 IU/ml at treatment week 4, week 12 or week 24 (A2)']
    });
    pushNotes(h.rx[0]);
    addRiba(h);
    if ( h.genotype.match(/1a/) ) {
        h.rx[0].svr = svrx.gt1.sim_peg_riba.gt1a.default;
    }
    if ( h.genotype.match(/1b/) ) {
        h.rx[0].svr = svrx.gt1.sim_peg_riba.gt1b.default;
    }
    if ( h.f4 ) {
        h.rx[0].svr = svrx.gt1.sim_peg_riba.f4.default;
    }
    if ( h.fail && ! h.f4 ) {
        h.rx[0].svr = h.genotype.match(/1a/) ? svrx.gt1.sim_peg_riba.fail.gt1a : h.genotype.match(/1b/) ? svrx.gt1.sim_peg_riba.fail.gt1b : svrx.gt1.sim_peg_riba.fail.default;
    }

    // sof_led
    if ( ! hasHarvoniCI(h)) {
        h.rx.unshift({
            medication: [ drugs.sof_led ],
            duration: 12,
            svr: svrx.gt1.sof_led.default,
            rating: svrx.gt1.sof_led.rating.easl,
            notes: []
        });
        pushNotes(h.rx[0]);

        if ( h.genotype.match(/1a/) ) {
            h.rx[0].svr = svrx.gt1.sof_led.gt1a.default;
        }
        if ( h.genotype.match(/1b/) ) {
            h.rx[0].svr = svrx.gt1.sof_led.gt1b.default;
        }
        if ( h.f4 ) {
            addRiba(h);
            if ( negativePredictorsOfResponse(h) ) {
                h.rx[0].duration = 24;
                h.rx[0].rating = svrx.gt1.sof_led.fail.rating.easl;
                h.rx[0].svr = svrx.gt1.sof_led.fail.w24riba;
            }
            else {
                h.rx[0].rating = svrx.gt1.sof_led.f4.rating.easl;
                h.rx[0].svr = svrx.gt1.sof_led.f4.w12riba;
            }
            h.rx[0].notes.push(noRiba24weeks(svrx.gt1.sof_led.f4.w24));
        }
    }


    // viek and viek riba
    h.rx.unshift({
        medication: [ drugs.viek ],
        duration: 12,
        svr: svrx.gt1.viek.default,
        rating: svrx.gt1.viek.rating.easl,
        notes: []
    });
    pushNotes(h.rx[0]);

    if ( h.genotype.match(/1b/)) {
        h.rx[0].svr = svrx.gt1.viek.gt1b.default;
        if ( h.f4 ) {
            addRiba(h); 
            h.rx[0].svr = svrx.gt1.viek_riba.f4.gt1b;          
        }
        else if ( h.fail) {
            addRiba(h); 
            h.rx[0].svr = svrx.gt1.viek_riba.fail.gt1b;             
        }
    }
    else {
        addRiba(h);
        h.rx[0].svr = svrx.gt1.viek_riba.gt1a.default;
        if ( h.f4 ) {
            h.rx[0].duration = 24;
            h.rx[0].svr = svrx.gt1.viek_riba.f4.gt1a;
        }
        else if ( h.fail) {
            h.rx[0].svr = svrx.gt1.viek_riba.fail.gt1a;             
        }
    }

    // sof sim
    h.rx.unshift({
        medication: [ drugs.sof, drugs.sim ],
        duration: 12,
        svr: svrx.gt1.sof_sim.default,
        rating: svrx.gt1.sof_sim.rating.easl,
        notes: []
    });
    pushNotes(h.rx[0]);

    if ( h.genotype.match(/1b/) ) {
        h.rx[0].svr = svrx.gt1.sof_sim.gt1b.default;
    }
    else {
        h.rx[0].svr = svrx.gt1.sof_sim.gt1a.default;        
    }
    if ( h.fail ) {
        h.rx[0].svr = svrx.gt1.sof_sim.fail.w12;
    }
    if ( h.f4 ) {
        addRiba(h);
        h.rx[0].svr = svrx.gt1.sof_sim.f4.w12riba;
        h.rx[0].notes.push(noRiba24weeks(svrx.gt1.sof_sim.f4.w24));
    }


    // sof dac
    h.rx.unshift({
        medication: [ drugs.sof, drugs.dac ],
        duration: 12,
        svr: svrx.gt1.sof_dac.default,
        rating: svrx.gt1.sof_dac.rating.easl,
        notes: []
    });
    pushNotes(h.rx[0]);

    if ( h.genotype.match(/1b/) ) {
        h.rx[0].svr = svrx.gt1.sof_dac.gt1b.default;
    }
    else {
        h.rx[0].svr = svrx.gt1.sof_dac.gt1a.default;        
    }
    if ( h.f4 ) {
        addRiba(h);
        h.rx[0].svr = svrx.gt1.sof_dac.f4.default;
        h.rx[0].notes.push(noRiba24weeks(svrx.gt1.sof_led.f4.default));
    }

}

function rxGT2EASL (h) {

    // sof riba
    h.rx.unshift({
        medication: [ drugs.sof ],
        duration: 12,
        svr: svrx.gt2.sof_riba.default,
        rating: svrx.gt2.sof_riba.rating.easl,
        notes: []
    });
    pushNotes(h.rx[0]);
    addRiba(h);

    if ( h.f4 || h.fail ) {
        h.rx[0].svr = h.f4 ? svrx.gt2.sof_riba.f4.default : svrx.gt2.sof_riba.fail.default;
        h.rx[0].rating = svrx.gt2.sof_riba.f4.rating.easl;
        h.rx[0].duration = 16;
        h.rx[0].notes.push(greenText('Therapy should be prolonged to 16 or 20 weeks in patients with cirrhosis, especially if they are treatment experienced.'));
    }

    // sof peg riba
    h.rx.unshift({
        medication: [ drugs.sof, drugs.peg ],
        duration: 12,
        svr: svrx.gt2.sof_peg_riba.default,
        rating: svrx.gt2.sof_peg_riba.rating.easl,
        notes: []
    });
    pushNotes(h.rx[0]);
    addRiba(h);

    // sof dac
    h.rx.unshift({
        medication: [ drugs.sof, drugs.dac ],
        duration: 12,
        svr: svrx.gt2.sof_dac.default,
        rating: svrx.gt2.sof_dac.rating.easl,
        notes: []
    });
    pushNotes(h.rx[0]);
    pushNotes(greenText('In AI444040 96% (25/26) patients achieved SVR12 after 24 weeks treatment.'));

}
function rxGT3EASL (h) {

    // sof peg riba
    h.rx.unshift({
        medication: [ drugs.sof, drugs.peg ],
        duration: 12,
        svr: svrx.gt3.sof_peg_riba.default,
        rating: svrx.gt3.sof_peg_riba.rating.easl,
        notes: []
    });
    pushNotes(h.rx[0]);
    addRiba(h);

    // sof riba
    h.rx.unshift({
        medication: [ drugs.sof ],
        duration: 24,
        svr: svrx.gt3.sof_riba.default,
        rating: svrx.gt3.sof_riba.rating.easl,
        notes: []
    });
    pushNotes(h.rx[0]);
    addRiba(h);

    if ( h.f4 || h.fail ) {
        h.rx[0].duration = 24;
        h.rx[0].svr = (h.fail && h.f4) ? svrx.gt3.sof_riba.fail.f4 : h.fail ? svrx.gt3.sof_riba.fail.default : svrx.gt3.sof_riba.f4.default;
        h.rx[0].notes.push(redText(' This therapy is suboptimal in treatment-experienced cirrhotic patients and in patients who failed to achieve an SVR after sofosbuvir plus ribavirin treatment, who should be offered an alternative treatment option (B1)'));
    }

    // sof dac
    h.rx.unshift({
        medication: [ drugs.sof, drugs.dac ],
        duration: 12,
        svr: svrx.gt3.sof_dac.default,
        rating: svrx.gt3.sof_dac.rating.easl,
        notes: []
    });
    pushNotes(h.rx[0]);
    if ( h.f4 ) {
        addRiba(h,true);
        h.rx[0].duration = 24;
        h.rx[0].svr = h.fail ? svrx.gt3.sof_dac.fail.riba24 : svrx.gt3.sof_riba.f4.riba24;
        h.rx[0].notes.push(greenText('EASL Guidelines 2015 say add Riba for 24 weeks pending clarification  but AASLD 2015 n=468 GT3 F3/F4 series showed inferior performance in all 24 week + Riba groups. For F4 SVR was 90% and treatment-experienced 86% http://www.clinicaloptions.com/Hepatitis/Conference%20Coverage/AASLD%202015/Highlights/Capsules/206.aspx'))
    }

}
function rxGT4EASL (h) {
    blockMessage('EASL GT4 not yet implemented',2000);
}
function rxGT5EASL (h) {
    blockMessage('EASL GT5 not yet implemented',2000);
}
function rxGT6EASL (h) {
    blockMessage('EASL GT6 not yet implemented',2000);
}

/*
*
*
*
* AASLD 2015
*
*
*
*/

function rxGT1AASLD (h) {
    if ( h.fail ) {
        if ( h.past == 'PEGRIBA' ) {
            rxGT1AASLDpegriba(h);
        }
        else if ( h.past == 'SOFRIBA') {
            rxGT1AASLDsofriba(h);
        }
        else if ( h.past == 'PROTEASE' ) {
            rxGT1AASLDprotease(h);
        }
        else if ( h.past == 'SOFNS5A' ) {
            rxGT1AASLDsofNS5A(h);
        }
        else {
            alert('Error - unhandled failure case: ' + h.past )
        }
    }
    else {
        if ( h.genotype.match(/1b/) ) {
            rxGT1AASLDnaive1b(h);
        }
        else {
            rxGT1AASLDnaive1a(h);       
        }
    }
}

function rxGT1AASLDnaive1a (h) {

    // sofosbuvir daclatasvir
    h.rx.unshift({ 
        medication:[ drugs.sof, drugs.dac ], 
        duration: 12,
        svr: svrx.gt1.sof_dac.gt1a.default, 
        rating: svrx.gt1.sof_dac.gt1a.rating,
        notes: drugs.dac.notes.slice()
    });
    if ( h.f4 ) {
        h.rx[0].duration = 24;
        h.rx[0].svr = svrx.gt1.sof_dac.gt1a.f4.default;
        h.rx[0].rating = svrx.gt1.sof_dac.gt1a.f4.rating;
        addRiba(h,true);

    }
    // harvoni
    if ( ! hasHarvoniCI(h)) {
        h.rx.unshift({
            medication: [ drugs.sof_led ],
            duration: 12,
            svr: svrx.gt1.sof_led.gt1a.default,
            rating: svrx.gt1.sof_led.gt1a.rating,           
            notes: drugs.sof_led.notes.slice()
        });
    }
    // viekira pak
    h.rx.unshift({
        medication: [ drugs.viek, drugs.viekx ],
        duration: 12,
        svr: svrx.gt1.viek.gt1a.default,
        rating: svrx.gt1.viek.gt1a.rating,
        notes: drugs.viek.notes.slice()
    });
    addRiba(h);    
    if ( h.f4 ) {
        h.rx[0].duration = 24;
        h.rx[0].svr = svrx.gt1.viek.gt1a.f4.default;
        h.rx[0].rating = svrx.gt1.viek.gt1a.f4.rating;
    }
    // sofosbuvir simeprevir
    h.rx.unshift({ 
        medication:[ drugs.sof, drugs.sim ], 
        duration: 12,
        svr: svrx.gt1.sof_sim.gt1a.default,
        rating: svrx.gt1.sof_sim.gt1a.rating, 
        notes: drugs.sim.notes.slice()
    });
    if ( h.f4 ) {
        h.rx[0].duration = 24;
        h.rx[0].svr = svrx.gt1.sof_sim.gt1a.f4.default;
        h.rx[0].rating = svrx.gt1.sof_sim.gt1a.f4.rating;    
        addRiba(h,true);
    }

}

function rxGT1AASLDnaive1b (h) {

    // sofosbuvir daclatasvir
    h.rx.unshift({ 
        medication:[ drugs.sof, drugs.dac ], 
        duration: 12,
        svr: svrx.gt1.sof_dac.gt1b.default, 
        rating: svrx.gt1.sof_dac.gt1b.rating,
        notes: drugs.dac.notes.slice()
    });
    if ( h.f4 ) {
        h.rx[0].duration = 24;
        h.rx[0].svr = svrx.gt1.sof_dac.gt1b.f4.default;
        h.rx[0].rating = svrx.gt1.sof_dac.gt1b.f4.rating;
        addRiba(h,true);

    }
    // harvoni
    if ( ! hasHarvoniCI(h)) {
        h.rx.unshift({
            medication: [ drugs.sof_led ],
            duration: 12,
            svr: svrx.gt1.sof_led.gt1b.default,
            rating: svrx.gt1.sof_led.gt1b.rating,           
            notes: drugs.sof_led.notes.slice()
        });
    }
    // viekira pak
    h.rx.unshift({
        medication: [ drugs.viek, drugs.viekx ],
        duration: 12,
        svr: svrx.gt1.viek.gt1b.default,
        rating: svrx.gt1.viek.gt1b.rating,
        notes: drugs.viek.notes.slice()
    });

    // sofosbuvir simeprevir
    h.rx.unshift({ 
        medication:[ drugs.sof, drugs.sim ], 
        duration: 12,
        svr: svrx.gt1.sof_sim.gt1b.default,
        rating: svrx.gt1.sof_sim.gt1b.rating, 
        notes: drugs.sim.notes.slice()
    });
    if ( h.f4 ) {
        h.rx[0].duration = 24;
        h.rx[0].svr = svrx.gt1.sof_sim.gt1b.f4.default;
        h.rx[0].rating = svrx.gt1.sof_sim.gt1b.f4.rating;    
        addRiba(h,true);
    }

}

function rxGT1AASLDpegriba (h) {
    //alert(arguments.callee.name)
    blockMessage('AASLD xGT1AASLDpegriba not yet implemented',2000);
}

function rxGT1AASLDsofriba (h) {
    alert(arguments.callee.name)
    blockMessage('AASLD rxGT1AASLDsofriba not yet implemented',2000);
}

function rxGT1AASLDprotease (h) {
    alert(arguments.callee.name)
    blockMessage('AASLD rxGT1AASLDprotease not yet implemented',2000);
}

function rxGT1AASLDsofNS5A (h) {
    blockMessage('AASLD GT1AASLDsofNS5A not yet implemented',2000);
}

function rxGT2AASLD (h) {
    blockMessage('AASLD GT2 not yet implemented',2000);
}
function rxGT3AASLD (h) {
    blockMessage('AASLD GT3 not yet implemented',2000);
}
function rxGT4AASLD (h) {
    blockMessage('AASLD GT4 not yet implemented',2000);
}
function rxGT5AASLD (h) {
    blockMessage('AASLD GT5 not yet implemented',2000);
}
function rxGT6AASLD (h) {
    blockMessage('AASLD GT6 not yet implemented',2000);
}

/*
*
*
*
* PEG/Riba Free
*
*
*
*/

function rxGT1 (h) {
    blockMessage('PEG Riba Free GT1 not yet implemented',2000);
}

function rxGT2 (h) {
    blockMessage('PEG Riba Free GT2 not yet implemented',2000);
}

function rxGT3 (h) {
    blockMessage('PEG Riba Free GT3 not yet implemented',2000);
}

function rxGT4 (h) {
    blockMessage('PEG Riba Free GT4 not yet implemented',2000);
}

function rxGT5 (h) {
    blockMessage('PEG Riba Free GT5 not yet implemented',2000);
}

function rxGT6 (h) {
    blockMessage('PEG Riba Free GT6 not yet implemented',2000);
}

function pushNotes (rx) {

    for ( var m in rx.medication ) {
        for ( var i in rx.medication[m].notes ) {
            rx.notes.push(rx.medication[m].notes[i]);
        }
    }
}

function hasHarvoniCI (h) {

    if (h.harvoniCI) {
        var msg = redText('Sofosbuvir/Ledipasvir not being recommended due to Harvoni CI(s)');
        blockMessage(msg);
        h.rx[0].notes.push(msg);
        return true;
    }
    return false;
}

function negativePredictorsOfResponse (h) {
    if ( h.f4 && (h.fail || h.platelets < 75) ) {
        return true;
    }
    else {
        return false;
    }
}

function noRiba24weeks(svr) {

    return greenText('Can use 24 weeks without Ribavrin in patients with contraindications or poor tolerance to ribavirin. Expected SVR: ' + svr +'%')
}

function addRiba(h,optional) {

    if (! h.riba) {
        var msg = 'Sorry, we can\'t accurately add Ribavirin without Ribavirin details. Please add them and recalculate.';
        $("#riba").prop('checked', true);
        $("#ribavirin").show();
        errorDialog(msg, "#platelets");
        h.rx[0].notes.push(redText(msg));
    }
    var ribaDose = h.riba ? calcRibaDose(h) : 1000;
    // need to clone drugs.riba so we can have multiple riba notes associated with various rx options
    var riba = $.extend(true,{},drugs.riba);
    riba.optional = optional ? true : false;
    riba.dose = [ribaDose + 'mg'];
    h.rx[0].medication.push(riba);
    if (riba.optional) {
        h.rx[0].notes.push(greenText('Ribavirin is optional'));
    }
    else {
        h.rx[0].notes.push(redText('Ribavirin is mandatory'));        
    }
    h.rx[0].notes.push('Ribavirin use requires frequent monitoring for pancytopaenia');
    if ( h.platelets < 50 ) h.rx[0].notes.push(redText('Low platelets are a relative contraindication to Ribavirin'));
    h.rx[0].notes.push('Ribavirin (200mg Capsules): ' + calcRibaCaps(ribaDose));
    h.rx[0].notes.push('Ribavirin (Ibavyr 400mg &amp; 600mg Tablets): ' + calcRibaTabs(ribaDose));
}

function setRibaWeight() {

    var guidelines= $("input[name=guidelines]:checked").val();
    if ( guidelines == 'AUS' || guidelines == 'AASLD' || guidelines == 'EASL') {
        $("#weightFull").hide();
        $("#weight75").show();
        $("#sfw").show();
        $("#sfwHR").hide();
    }
    else {
        $("#weightFull").show();
        $("#weight75").hide();
    }
}

function showFullWeightOptions() {

    $('#weightFull').show()
    $('#sfw').hide();
    $('#sfwHR').show();
}

function calcRibaDose (h) {

    if ( ! h.riba ) return 0;
    var dose = 0;
    if ( h.weight == '>105' ) {
        dose = 1400;
    }
    else if ( h.weight == '81-105' || h.weight == '>75' ) {
        dose = 1200;
    }
    else if ( h.weight == '66-80' || h.weight == '<75' ) {
        dose = 1000;  
    }
    else if ( h.weight == '<66' ) {
        dose = 800;
    }
    else {
        alert('Error for weight: ' + h.weight );
    }
    if ( h.eGFR < 60 ) {
        h.rx[0].notes.push(redText('Specialist advice highly recommended about Ribavirin dose'));
        dose =  h.eGFR > 30 ? dose/2 : dose/3;
    }
  
    return 100 * Math.round(dose/100);
}

// standard Riba formulation is 200 mg capsules
function calcRibaCaps (dose) {

    if ( dose >=1400 ) {
        return '3 in the morning 4 at night';
    }
    if ( dose >=1200 ) {
        return '3 in the morning 3 at night';
    }
    if ( dose >=1000 ) {
        return '2 in the morning 3 at night';
    }
    if ( dose >=800 ) {
        return '2 in the morning 2 at night';
    }
    if ( dose >=600 ) {
        return '1 in the morning 2 at night';
    }
    if ( dose >=400 ) {
        return '1 in the morning 1 at night';
    }
    if ( dose >=300 ) {
        return 'Alternating doses, 1 daily alternating with 2 daily every other day';
    }
    if ( dose >=200 ) {
        return '1 daily';
    }
    return redText('No Riba dose!');
}

// Ibavyr tablets come in 400mg and 600mg scored
function calcRibaTabs (dose) {

    if ( dose >=1400 ) {
        return '2 x 400mg in the morning 600mg at night';
    }
    if ( dose >=1200 ) {
        return '600 mg morning and night';
    }
    if ( dose >=1000 ) {
        return '600mg in the morning 400mg at night';
    }
    if ( dose >=800 ) {
        return '400mg morning and night';
    }
    if ( dose >=600 ) {
        return '&frac12; 600mg morning and night';
    }
    if ( dose >=400 ) {
        return '&frac12; 400mg morning and night';
    }
    if ( dose >=300 ) {
        return '&frac12; 600mg daily';
    }
    if ( dose >=200 ) {
        return '&frac12; 400mg daily';
    }
    return redText('No Riba dose!');
}

function setFibrosisFromKPa () {

    var kpa = parseFloat($("#kpa").val());

    if (isNaN(kpa)) {
        return;
    }

    if ( kpa >= 14.5 ) {
        $("#fibrosis").val('F4');
    }
    else if ( kpa >= 12.5 ) {
        $("#fibrosis").val('F3-F4');
    }
    else if ( kpa >= 9.5 ) {
        $("#fibrosis").val('F3');
    }
    else if ( kpa >= 8.5 ) {
        $("#fibrosis").val('F2');
    }
    else if ( kpa >= 7 ) {
        $("#fibrosis").val('F1-F2');
    }
    else {
        $("#fibrosis").val('F0-F1'); 
    }
 
}

function setFibrosisHepascore () {

    var hepascore = parseFloat($("#hepascore").val());

    if (isNaN(hepascore)) {
        return;
    }

    if ( hepascore >= 0.7 ) {
        $("#fibrosis").val('F4');
    }
    else if ( hepascore >= 0.5 ) {
        $("#fibrosis").val('F3-F4');
    }
    else if ( hepascore >= 0.3 ) {
        $("#fibrosis").val('F2');
    }
    else if ( hepascore >= 0.15 ) {
        $("#fibrosis").val('F1');
    }
    else {
        $("#fibrosis").val('F0-F1');
    }
}

function setFibrosisELFscore () {

    var ELFscore = parseFloat($("#ELFscore").val());

    if (isNaN(ELFscore)) {
        return;
    }

    if ( ELFscore > 11.3 ) {
        $("#fibrosis").val('F4');
    }
    else if ( ELFscore >= 9.8 ) {
        $("#fibrosis").val('F3');
    }
    else if ( ELFscore >= 7.7 ) {
        $("#fibrosis").val('F2');
    }
    else {
        $("#fibrosis").val('F1');
    }
}

function toggleRiba () {

    $("#riba:checked").length == 1 ? $("#ribavirin").slideDown() : $("#ribavirin").hide(400);
}

function blockMessage(message,timeout) {

    if (timeout === undefined) timeout = 3000;
    $.blockUI({ 
        message: message, 
        css: {
            border: 'none',
            top: '100px',
            padding: '10px 20px',
            backgroundColor: 'rgba(255, 255, 255, 1)',
            '-webkit-border-radius': '10px',
            '-moz-border-radius': '10px',
            'border-radius': '10px',
            color: '#000'
        },
        timeout: timeout,
    });
}

function redText(text) {

    return '<span class="red">' + text + '</span>';
}

function greenText(text) {

    return '<span class="green">' + text + '</span>';
}

function errorDialog(text,e) {

    $('#error').html(redText(text)).dialog({
        title: "Error",
        modal: true,
        open: function(event, ui) { $('.ui-widget-overlay').bind('click', function(){ $("#error").dialog('close'); $(e).select().focus() } ) }
    })
};

function evidence() {
    if ($("input[name=guidelines]:checked").val() == 'AASLD') {
        $("#gradingAASLD").dialog({
            title: 'AASLD Grading System Used For Guidelines',
            width: "80%",
            modal: true,
            open: function(event, ui) { $('.ui-widget-overlay').bind('click', function(){ $("#gradingAASLD").dialog('close') } ) }
        });
    }
    else {
        $("#gradingEASL").dialog({
            title: 'EASL Grading System Used For Guidelines',
            width: "80%",
            modal: true,
            open: function(event, ui) { $('.ui-widget-overlay').bind('click', function(){ $("#gradingEASL ").dialog('close') } ) }
        });
    }
}

</script>

<div id="dataInput">
<div style="float:left;padding:4px 40px 0 0"><b>HCV Decision Support Tool</b></div>
<div style="float:left;" id="google_translate_element"></div>
<div style="clear:both"></div>
<hr>
<script type="text/javascript">
function googleTranslateElementInit() {
  new google.translate.TranslateElement({pageLanguage: 'en', layout: google.translate.TranslateElement.InlineLayout.SIMPLE}, 'google_translate_element');
}
</script>
<script type="text/javascript" src="https://translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script>
  <table>
    <tr>
      <td>
        <label>Genotype</label>
      </td>
      <td>
        <select id="genotype">
          <option></option>
          <option>1</option>
          <option>1a</option>
          <option>1b</option>
          <option>2</option>
          <option>2a</option>
          <option>2b</option>
          <option>3</option>
          <option>3a</option>
          <option>3b</option>
          <option>4</option>
          <option>5</option>
          <option>6</option>
          <option>Unknown</option>
        </select>
      </td>
    </tr>
    <tr>
      <td>
        <label>Fibrosis</label>
      </td>
      <td>
        <select id="fibrosis">
          <option></option>
          <option>F0</option>
          <option>F0-F1</option>
          <option>F1</option>
          <option>F1-F2</option>
          <option>F2</option>
          <option>F2-F3</option>
          <option>F3</option>
          <option>F3-F4</option>
          <option>F4</option>
        </select>
        <span class="nowrap"> kPa <input type="text" class="narrow" id="kpa" onblur="setFibrosisFromKPa()"></span>
        <span class="nowrap"> Hepascore <input type="text" class="narrow" id="hepascore" onblur="setFibrosisHepascore()"></span>
        <span class="nowrap"> ELF Score <input type="text" class="narrow" id="ELFscore" onblur="setFibrosisELFscore()"></span>
      </td>
    </tr>
    <tr>
      <td>
        <label>Past Treatment</label>
      </td>
      <td>
        <select id="past">
          <option></option>
          <option value="naive">Naive</option>
          <option value="PEG">Failed Interferon</option>
          <option value="PEGRIBA">Failed Interferon + Riba</option>
          <option value="PROTEASE">Failed Protease + Interferon + Riba</option>
          <option value="PROTEASE">Failed Simeprevir + Sofosbuvir (no prior NS5A treatment)</option>
          <option value="SOFRIBA">Failed Sofosbuvir + Ribavirin +/- Interferon</option>
          <option value="SOFNS5A">Failed Sofosbuvir + NS5A (Led or Dac) or Viekira Pak</option>
        </select>
      </td>
    </tr>
    <tr>
      <td>
        <label>Harvoni CI<label>
      </td>
      <td>
        <input type="radio" name="harvoniCI" value="no"> No
        <input type="radio" name="harvoniCI" value="yes"> Yes (Amiodarone, Anticonvulsants, Antacids/PPIs/H2 blockers, St John's Wort)</td>
    </tr>
    <tr>
      <td>
        <label>Guidelines<label>
      </td>
      <td>
        <input type="radio" name="guidelines" value="AUS" checked="checked" onChange="setRibaWeight()"> AUS
        <input type="radio" name="guidelines" value="EASL" onChange="setRibaWeight()"> EASL
        <input type="radio" name="guidelines" value="AASLD" onChange="setRibaWeight()"> AASLD
        <input type="radio" name="guidelines" value="FIXHEPC" onChange="setRibaWeight()"> PEG/Riba Free
      </td>
    </tr>
    <tr>
      <td>
        <label>Ribavirin<label>
      </td>
      <td>
        <input type="checkbox" id="riba" onChange="toggleRiba()"> (Check this box to include ribavirin options)</td>
    </tr>
    <tr>
      <td> </td>
      <td>
        <fieldset id="ribavirin" style="display:none">
          <legend>Ribavirin Only</legend>
          <table>
            <tr>
              <td>
                <label>Platelets<label>
              </td>
              <td>
                <input type="text" class="narrow" id="platelets"> * If <50 Ribavirin presents significant risks
              </td>
            </tr>
            <tr>
              <td>
                <label>Weight<label>
              </td>
              <td>
                <div id="weightFull" style="display:none">
                <input type="radio" name="weight" value="&lt;66"> &lt; 66kg
                <input type="radio" name="weight" value="66-80"> 66-80kg
                <input type="radio" name="weight" value="81-105"> 81-105kg
                <input type="radio" name="weight" value="&gt;105"> &gt; 105kg
                </div>
                <div id="weight75" style="clear:left">
                <hr id="sfwHR" style="display:none">
                <input type="radio" name="weight" value="&lt;75"> &lt; 75kg
                <input type="radio" name="weight" value="&gt;75"> &gt; 75kg
                <a id="sfw" href="javascript:showFullWeightOptions()">Show full weight options</a>
                </div>
              </td>
            </tr>
            <tr>
              <td>
                <label>eGFR<label>
              </td>
              <td>
                <input type="text" class="narrow" id="eGFR"> * Dose adjustment with CRF will be calculated
              </td>
            </tr>
          </table>
        </fieldset>
      </td>
    </tr>
    <tr>
      <td> </td>
      <td>
        <input type="button" value="Calculate" id="calculate" onclick="supportDecision()">
      </td>
    </tr>
  </table>
  <hr>
</div>

<div id="demographics">

<p>Please make your selections and press the calculate button</p>

<p>THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.</p>

</div>

<div id="rx"></div>

<div id="error"></div>

<div id="gradingAASLD" class="grading" style="display:none;">

<div class="title">Class I</div>
<div class="description">Conditions for which there is evidence and/or general agreement that a given diagnostic evaluation, procedure, or treatment is beneficial, useful, and effective</div>

<div class="title">Class II</div>
<div class="description">Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness and efficacy of a diagnostic evaluation, procedure, or treatment</div>

<div class="title">Class IIa</div>
<div class="description">Weight of evidence and/or opinion is in favor of usefulness and efficacy</div>

<div class="title">Class IIb</div>
<div class="description">Usefulness and efficacy are less well established by evidence and/or opinion</div>

<div class="title">Class III</div>
<div class="description">Conditions for which there is evidence and/or general agreement that a diagnostic evaluation, procedure, or treatment is not useful and effective or if it in some cases may be harmful</div>

<hr>

<div class="title">Evidence Quality</div>

<div class="title">Level A</div>
<div class="description">Data derived from multiple randomized clinical trials or meta-analyses</div>

<div class="title">Level B</div>
<div class="description">Data derived from a single randomized trial, or nonrandomized studies</div>

<div class="title">Level C</div>
<div class="description">Consensus opinion of experts, case studies, or standard of care</div>

</div>

<div id="gradingEASL" class="grading" style="display:none;">

<div class="title">Evidence Quality</div>

<div class="title">A - High</div>
<div class="description">Further research is very unlikely to change our confidence in the estimate of effect</div>

<div class="title">B - Moderate</div>
<div class="description">Further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate</div>

<div class="title">C - Low</div>
<div class="description">Further research is very likely to have an important impact on our confidence in the estimate of effect and
is likely to change the estimate. Any change of estimate is uncertain</div>

<hr>

<div class="title">Recommendation</div>

<div class="title">1 - Strong</div> 
<div class="description">Factors influencing the strength of the recommendation included the quality of the evidence, presumed
patient-important outcomes, and cost</div>

<div class="title">2 - Weak</div> 
<div class="description">Variability in preferences and values, or more uncertainty. Recommendation is made with less certainty,
higher cost or resource consumption</div>

</div>

</body>

</html>
